Actively Recruiting
Real-World Study of Guselkumab in Adults with Psoriatic Arthritis Evaluated by Ultrasound Imaging
Led by Janssen Research & Development, LLC · Updated on 2026-11-03
200
Participants Needed
21
Research Sites
47 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating how well guselkumab works to improve symptoms of psoriatic arthritis, an inflammatory joint disease affecting people with psoriasis, which causes red, scaly skin patches. This observational study uses musculoskeletal ultrasound MSUS to assess disease activity and treatment effects in a real-world setting, focusing on participants with active psoriatic arthritis. Participants with confirmed psoriatic arthritis who are treated with guselkumab according to standard clinical practice are enrolled. No study drug is provided instead, data from routine clinical care, including ultrasound results, are collected. Participants will also answer questions about their health and well-being. The study tracks outcomes such as reductions in synovitis scores, disease activity indices, enthesitis resolution, pain scores, and treatment persistence over periods extending up to 52 weeks. During the study, participants undergo assessments at baseline and at weeks 12, 24, and 52, including ultrasound examinations and clinical evaluations. Researchers measure outcomes like global synovitis scores, disease activity, minimal disease activity achievement, and adverse events. Data collection aligns with routine care visits, allowing long-term monitoring of treatment effects and safety. The study is sponsored by Janssen Research & Development, LLC and runs from December 2025 until June 2028.
CONDITIONS
Brief Title
A Study of Guselkumab in Participants With Psoriatic Arthritis (PsA) in a Real-World Setting
Research Team
S
Study Contact
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here